PUBLICATIONS OUR PIPELINE OUR SAB Discovering New Mechanisms to Solve Significant Medical Challenges For decades, the gut had been under-recognized as a viable site for new therapeutic points of intervention for treating disease. Using our discovery model, which recreates environments within certain areas of the gastrointestinal tract and kidney, Ardelyx scientists have been able to elucidate new and previously unexploited ion transport mechanisms. Focusing on these mechanisms, we are creating targeted, small molecule drugs that are orally active but with limited systemic absorption, aiming to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Our novel biological insights have enabled us to develop a pipeline of drug candidates that specifically target these mechanisms, with the potential to benefit large populations of underserved patients. Our lead candidate tenapanor, discovered and developed by Ardelyx, is a first-in-class, targeted therapy for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a unique mechanism of action and acts locally in the gut to inhibit the sodium/hydrogen exchanger 3 (NHE3). This results in a conformational change of the epithelial cell junctions, reducing permeability specific to phosphate, resulting in decreased phosphate absorption through the paracellular pathway, the primary pathway of dietary phosphate absorption. Tenapanor has the potential to provide a novel approach for the treatment of hyperphosphatemia (elevated serum phosphorus), a major co-morbidity factor in people with CKD and a significant unmet medical need. Our discovery platform has also enabled the systematic study of the biological mechanisms of potassium secretion and has led us to the discovery of our lead candidate in the RDX013 program that pharmacologically targets potassium secretion through the lumen of the gut, thus lowering levels of serum potassium. High serum potassium, a condition called hyperkalemia, is a common problem in patients with kidney and heart disease and can cause a significantly increased risk of death because of the potential for heart conductance issues Our unique discovery platform and deep understanding of the primary mechanism of sodium transport in the intestine resulted in our discovery and development of IBSRELA® (tenapanor), a first-in-class therapy that received approval in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). We are pursuing strategic collaborations for IBSRELA for IBS-C in the U.S. and have established commercialization agreements with Fosun Pharma in China and Knight in Canada for this indication. Scientific Publications IBS-C Hyperphosphatemia General Clinical Research Bay Area 34175 Ardenwood Boulevard Fremont, CA 94555 Greater Boston 400 Fifth Avenue, Suite 210 Waltham, MA 02451 Phone: 510.745.1700 Inquiries: General: info@ardelyx.com Media: media@ardelyx.com Investor: investor@ardelyx.com Business Development: partnering@ardelyx.com © 2021 Ardelyx® Terms & Conditions · Privacy Policy Expanded Access · Forward Looking Statements SITE DESIGN BY D&CO We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits, as explained in our Privacy & Cookies Policy. By clicking “Accept”, you consent to the use of ALL the cookies. Accept